{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:42:33Z","timestamp":1782974553231,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Die Antibiotikaverordnung bei station\u00e4ren Patienten unterscheidet sich je nach Fachrichtung sowohl hinsichtlich der Intensit\u00e4t als auch bez\u00fcglich des Wirkstoffspektrums.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Es wird eine Analyse und Bewertung der aktuellen Daten zur Antibiotikaverbrauchsdichte (AD) in deutschen urologischen Fachabteilungen durchgef\u00fchrt.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Die Antibiotikaverordnungsdaten von 107 urologischen Fachabteilungen wurden f\u00fcr den Zeitraum 2022\/23 ausgewertet. Die Berechnung der AD erfolgte als Tagesdosen (festgelegt nach Empfehlungen f\u00fcr erwachsene station\u00e4re Patienten, sog. \u201erecommended daily doses\u201c, RDD) pro 100 Pflegetage (RDD\/100).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>Die AD betrug im Median\u00a071 RDD\/100 mit einer gro\u00dfen Spannweite von minimal 15,9 bis maximal 138,7\u00a0RDD\/100. Es gab keine signifikanten Unterschiede nach Krankenhausgr\u00f6\u00dfe. Fluorchinolone waren mit einer medianen AD von 6,0\u00a0RDD\/100 nach Cephalosporinen der dritten bzw. vierten Generation (Median 16,2\u00a0RDD\/100), Aminopenicillin\/Betalaktamaseinhibitor-Kombinationen (Median 10,8\u00a0RDD\/100) und Piperacillin-Tazobactam bzw. Piperacillin (Median\u00a08,9\u00a0RDD\/100) die viertst\u00e4rkste Substanzgruppe. Das Verh\u00e4ltnis Penicilline zu Cephalosporinen schwankte zwischen 6:94 und 98:2 (insgesamt 52:48). Aminoglykoside (&lt;\u202f1\u202f%) und intraven\u00f6ses Fosfomycin (&lt;\u202f0,1\u202f%) hatten nur einen sehr kleinen Anteil an den Verordnungen. Cotrimoxazol (Median\u00a04,0\u00a0RDD\/100) wurde seltener als Fluorchinolone verordnet. Der Anteil oraler Antibiotika betrug insgesamt 44,7\u202f% und schwankte nach Krankenhausgr\u00f6\u00dfe wenig. Dabei wurden Fosfomycin, Pivmecillinam, Nitrofurantoin und Nitroxolin deutlich seltener verordnet als orale Betalaktame, Fluorchinolone und Cotrimoxazol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Schlussfolgerung<\/jats:title>\n            <jats:p>Die AD in der Urologie schwankte auch 2022\/23 erheblich. Betalaktame wurden mit Abstand am h\u00e4ufigsten verordnet. Fluorchinolone \u2013\u00a0vielfach oral\u00a0\u2013 werden weiterhin eingesetzt, ihr Verbrauch schwankt \u00e4hnlich der gesamten AD erheblich und unabh\u00e4ngig von der Krankenhausgr\u00f6\u00dfe. Die bei der akuten unkomplizierten Zystitis empfohlenen Antibiotika spielen mengenm\u00e4\u00dfig im station\u00e4ren Setting eine untergeordnete Rolle. Penicilline und Cotrimoxazol sollten vermehrt als Behandlungsalternative ber\u00fccksichtigt werden. Auch intraven\u00f6ses Fosfomycin oder Aminoglykoside sollten als Optionen bei ansonsten resistenten Erregern betrachtet werden.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00120-024-02469-2","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:57:22Z","timestamp":1731977842000},"page":"165-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotikaverschreibung in urologischen Kliniken Deutschlands: Ergebnisse einer Querschnittstudie","Antibiotic prescribing practice in urological departments in Germany: results of a\u00a0cross-sectional study"],"prefix":"10.1007","volume":"64","author":[{"given":"Winfried V.","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesche","family":"F\u00f6rst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Kramme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Steib-Bauert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Magistro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"de With","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"2469_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00103-018-2727-x","volume":"61","author":"WV Kern","year":"2018","unstructured":"Kern\u00a0WV (2018) Rationale Antibiotikaverordnung in der Humanmedizin. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 61:580\u2013588. https:\/\/doi.org\/10.1007\/s00103-018-2727-x","journal-title":"Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz"},{"key":"2469_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00103-013-1764-8","volume":"56","author":"B Schweickert","year":"2013","unstructured":"Schweickert\u00a0B, Kern\u00a0WV, de With\u00a0K et\u00a0al (2013) Antibiotika-Verbrauchs-Surveillance \u2013 Ausf\u00fchrungen und Erl\u00e4uterungen zur Bekanntmachung \u201eFestlegung der Daten zu Art und Umfang des Antibiotika-Verbrauchs in Krankenh\u00e4usern nach \u00a7\u00a023 Abs.\u00a04 Satz\u00a02 IfSG\u201c. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 56:903\u2013912. https:\/\/doi.org\/10.1007\/s00103-013-1764-8","journal-title":"Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz"},{"key":"2469_CR3","unstructured":"- (2018) S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus AWMF-Registernummer 092\/001. https:\/\/register.awmf.org\/assets\/guidelines\/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02-abgelaufen.pdf;. Zugegriffen: 1. Mai 2024"},{"key":"2469_CR4","unstructured":"ECDC (2022) Antimicrobial consumption in the EU\/EEA (ESAC-Net)\u2014Annual Epidemiological Report for 2022. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER-antimicrobial-consumption.pdf;. Zugegriffen: 7. Mai 2024"},{"key":"2469_CR5","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/jac\/dky345","volume":"73","author":"B Schweickert","year":"2018","unstructured":"Schweickert\u00a0B, Feig\u00a0M, Schneider\u00a0M et\u00a0al (2018) Antibiotic consumption in Germany: first data of a\u00a0newly implemented web-based tool for local and national surveillance. J\u00a0Antimicrob Chemother 73:3505\u20133515. https:\/\/doi.org\/10.1093\/jac\/dky345","journal-title":"J Antimicrob Chemother"},{"key":"2469_CR6","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1055\/s-0041-105938","volume":"140","author":"WV Kern","year":"2015","unstructured":"Kern\u00a0WV, Fellhauer\u00a0M, Hug\u00a0M et\u00a0al (2015) Antibiotika-Anwendung 2012\/2013 in 109 deutschen Akutkrankenh\u00e4usern. Dtsch Med Wochenschr 140:e237\u201346. https:\/\/doi.org\/10.1055\/s-0041-105938","journal-title":"Dtsch Med Wochenschr"},{"key":"2469_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1055\/s-0042-121745","volume":"142","author":"K de With","year":"2017","unstructured":"de With\u00a0K, Wilke\u00a0K, F\u00f6rst\u00a0G, Kramme\u00a0E, Kern\u00a0WV (2017) Antibiotic Stewardship (ABS) in Akutkrankenh\u00e4usern \u2013 neue Erfahrungen und Empfehlungen. Dtsch Med Wochenschr 142:177\u2013182. https:\/\/doi.org\/10.1055\/s-0042-121745","journal-title":"Dtsch Med Wochenschr"},{"key":"2469_CR8","volume-title":"Swiss Antibiotic Resistance Report 2022 \u2013 Usage of Antibiotics and Occurrence of Antibiotic Resistance in Switzerland","author":"-","year":"2022","unstructured":"- (2022) Swiss Antibiotic Resistance Report 2022 \u2013 Usage of Antibiotics and Occurrence of Antibiotic Resistance in Switzerland. Federal Office of Public Health and Federal Food Safety and Veterinary Office"},{"key":"2469_CR9","volume-title":"DANMAP 2022\u2014Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark","author":"-","year":"2023","unstructured":"- (2023) DANMAP 2022\u2014Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. National Food Institute & Statens Serum Institut, Lyngby\/Copenhagen"},{"key":"2469_CR10","volume-title":"A\u00a0report on Swedish Antibiotic Sales and Resistance in Human Medicine (SWEDRES) and Swedish Veterinary Antibiotic Resistance Monitoring (SVARM) 2022","author":"-","year":"2023","unstructured":"- (2023) A\u00a0report on Swedish Antibiotic Sales and Resistance in Human Medicine (SWEDRES) and Swedish Veterinary Antibiotic Resistance Monitoring (SVARM) 2022. Public Health Agency of Sweden & National Veterinary Institute, Solna\/Uppsala"},{"key":"2469_CR11","unstructured":"NethMap 2022\u2014Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2021. SWAB\u2014the Dutch Foundation of the Working Party on Antibiotic Policy & RIVM\u2014the National Institute for Public Health and the Environment of the Netherlands, 2022."},{"key":"2469_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pathogens5010010","volume":"5","author":"F Wagenlehner","year":"2016","unstructured":"Wagenlehner\u00a0F, Tandogdu\u00a0Z, Bartoletti\u00a0R et\u00a0al (2016) The Global Prevalence of Infections in Urology Study: a\u00a0long-term, worldwide surveillance study on urological infections. Pathogens 5:10. https:\/\/doi.org\/10.3390\/pathogens5010010","journal-title":"Pathogens"},{"key":"2469_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00877-9","author":"A Simoni","year":"2024","unstructured":"Simoni\u00a0A, Schwartz\u00a0L, Junquera\u00a0GY, Ching\u00a0CB, Spencer\u00a0JD (2024) Current and emerging strategies to curb antibiotic-resistant urinary tract infections. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-024-00877-9","journal-title":"Nat Rev Urol"},{"key":"2469_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000487645","volume":"100","author":"J Kranz","year":"2018","unstructured":"Kranz\u00a0J, Schmidt\u00a0S, Lebert\u00a0C et\u00a0al (2018) The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int 100:271\u2013278. https:\/\/doi.org\/10.1159\/000487645","journal-title":"Urol Int"},{"key":"2469_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","volume":"86","author":"J Kranz","year":"2024","unstructured":"Kranz\u00a0J, Bartoletti\u00a0R, Bruy\u00e8re\u00a0F et\u00a0al (2024) European Association of Urology guidelines on urological infections: summary of the 2024 guidelines. Eur Urol 86:27\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.035","journal-title":"Eur Urol"},{"key":"2469_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s15010-008-8138-4","volume":"37","author":"K de With","year":"2009","unstructured":"de With\u00a0K, Bestehorn\u00a0H, Steib-Bauert\u00a0M et\u00a0al (2009) Comparison of defined versus recommended versus prescribed daily doses for measuring hospital antibiotic consumption. Infection 37:349\u2013352. https:\/\/doi.org\/10.1007\/s15010-008-8138-4","journal-title":"Infection"},{"key":"2469_CR17","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/jac\/dkx244","volume":"72","author":"G F\u00f6rst","year":"2017","unstructured":"F\u00f6rst\u00a0G, de With\u00a0K, Weber\u00a0N et\u00a0al (2017) Validation of adapted daily dose definitions for hospital antibacterial drug use evaluation: a\u00a0multicentre study. J\u00a0Antimicrob Chemother 72:2931\u20132937. https:\/\/doi.org\/10.1093\/jac\/dkx244","journal-title":"J Antimicrob Chemother"},{"key":"2469_CR18","doi-asserted-by":"publisher","first-page":"ofz216","DOI":"10.1093\/ofid\/ofz216","volume":"6","author":"GJ Germanos","year":"2019","unstructured":"Germanos\u00a0GJ, Trautner\u00a0BW, Zoorob\u00a0RJ et\u00a0al (2019) No clinical benefit to treating male urinary tract infection longer than seven days: an outpatient database study. Open Forum Infect Dis 6:ofz216. https:\/\/doi.org\/10.1093\/ofid\/ofz216","journal-title":"Open Forum Infect Dis"},{"key":"2469_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1159\/000520564","volume":"106","author":"L Schneidewind","year":"2022","unstructured":"Schneidewind\u00a0L, Torabi\u00a0L, Dr\u00e4ger\u00a0DL, Hakenberg\u00a0OW (2022) Reduction of perioperative antibiotic prophylaxis in open radical cystectomy with ileal conduit is feasible: results of a\u00a0prospective clinical trial. Urol Int 106:825\u2013831. https:\/\/doi.org\/10.1159\/000520564","journal-title":"Urol Int"},{"key":"2469_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamasurg.2022.4729","volume":"157","author":"K He","year":"2022","unstructured":"He\u00a0K, Nayak\u00a0RB, Allori\u00a0AC et\u00a0al (2022) Correlation between postoperative antimicrobial prophylaxis use and surgical site infection in children undergoing nonemergent surgery. JAMA Surg 157:1142\u20131151. https:\/\/doi.org\/10.1001\/jamasurg.2022.4729","journal-title":"JAMA Surg"},{"key":"2469_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/antibiotics11030372","volume":"11","author":"O Joean","year":"2022","unstructured":"Joean\u00a0O, Tahedl\u00a0D, Flintrop\u00a0M et\u00a0al (2022) Clinical and microbiological effects of an antimicrobial stewardship program in urology\u2014a\u00a0single center before-after study. Antibiotics 11:372. https:\/\/doi.org\/10.3390\/antibiotics11030372","journal-title":"Antibiotics"},{"key":"2469_CR22","doi-asserted-by":"publisher","first-page":"106943","DOI":"10.1016\/j.ijantimicag.2023.106943","volume":"62","author":"M Batlle","year":"2023","unstructured":"Batlle\u00a0M, Badia\u00a0JM, Hern\u00e1ndez\u00a0S et\u00a0al (2023) Reducing the duration of antibiotic therapy in surgical patients through a\u00a0specific nationwide antimicrobial stewardship program. A\u00a0prospective, interventional cohort study. Int J Antimicrob Agents 62:106943. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106943","journal-title":"Int J Antimicrob Agents"},{"key":"2469_CR23","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.idnow.2023.104763","volume":"53","author":"PM Roger","year":"2023","unstructured":"Roger\u00a0PM, Bastian\u00a0S, Breurec\u00a0S, Sali\u00e8ge\u00a0M, Blanchet\u00a0P, Brureau\u00a0L (2023) Simplified antibiotic guidelines in urology are associated with decreased multidrug-resistant Enterobacterales. Infect Dis Now 53:104763. https:\/\/doi.org\/10.1016\/j.idnow.2023.104763","journal-title":"Infect Dis Now"},{"key":"2469_CR24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1080\/14740338.2022.2147924","volume":"21","author":"C Bove","year":"2022","unstructured":"Bove\u00a0C, Baldock\u00a0RA, Champigneulle\u00a0O, Martin\u00a0L, Bennett\u00a0CL (2022) Fluoroquinolones: old drugs, putative new toxicities. Expert Opin Drug Saf 21:1365\u20131378. https:\/\/doi.org\/10.1080\/14740338.2022.2147924","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2469_CR25","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.ijantimicag.2006.05.005","volume":"28","author":"TE Johansen","year":"2006","unstructured":"Johansen\u00a0TE, Cek\u00a0M, Naber\u00a0KG et\u00a0al (2006) Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents 28(1):S91\u2013S107. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.05.005","journal-title":"Int J Antimicrob Agents"},{"key":"2469_CR26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3389\/fmicb.2015.00546","volume":"6","author":"JW Dik","year":"2015","unstructured":"Dik\u00a0JW, Hendrix\u00a0R, Lo-Ten-Foe\u00a0JR et\u00a0al (2015) Automatic day\u20112 intervention by a\u00a0multidisciplinary antimicrobial stewardship-team leads to multiple positive effects. Front Microbiol 6:546. https:\/\/doi.org\/10.3389\/fmicb.2015.00546","journal-title":"Front Microbiol"},{"key":"2469_CR27","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1055\/a-0982-8842","volume":"145","author":"WV Kern","year":"2020","unstructured":"Kern\u00a0WV, Horn\u00a0S, Fink\u00a0G (2020) Aktuelle Entwicklungen im Bereich Antibiotic Stewardship. Dtsch Med Wochenschr 145:1758\u20131763. https:\/\/doi.org\/10.1055\/a-0982-8842","journal-title":"Dtsch Med Wochenschr"},{"key":"2469_CR28","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/1469-0691.12711","volume":"20","author":"SH Wie","year":"2014","unstructured":"Wie\u00a0SH, Kim\u00a0HW, Chang\u00a0UI (2014) Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae in elderly and non-elderly women. Clin Microbiol Infect 20:1211\u20131218. https:\/\/doi.org\/10.1111\/1469-0691.12711","journal-title":"Clin Microbiol Infect"},{"key":"2469_CR29","doi-asserted-by":"publisher","first-page":"e02165","DOI":"10.1128\/AAC.02165-18","volume":"63","author":"KJ Goodlet","year":"2018","unstructured":"Goodlet\u00a0KJ, Benhalima\u00a0FZ, Nailor\u00a0MD (2018) A\u00a0Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents Chemother 63:e2165\u201318. https:\/\/doi.org\/10.1128\/AAC.02165-18","journal-title":"Antimicrob Agents Chemother"},{"key":"2469_CR30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/jac\/dkaa148","volume":"75","author":"M Elbaz","year":"2020","unstructured":"Elbaz\u00a0M, Zadka\u00a0H, Weiss-Meilik\u00a0A, Ben-Ami\u00a0R (2020) Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J\u00a0Antimicrob Chemother 75:2307\u20132313. https:\/\/doi.org\/10.1093\/jac\/dkaa148","journal-title":"J Antimicrob Chemother"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02469-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02469-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02469-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T22:10:11Z","timestamp":1739571011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02469-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2469"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02469-2","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"8 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"W.V.\u00a0Kern, J.\u00a0Baumann, G.\u00a0F\u00f6rst, E.\u00a0Kramme, M.\u00a0Steib-Bauert, J.\u00a0Kranz, G.\u00a0Magistro und K.\u00a0de With geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}